Investigating how psilocybin affects nicotine use in rats
Set and setting: the effects of psilocybin on nicotine self-administration in rats
['FUNDING_R03'] · STATE UNIVERSITY OF NEW YORK AT BUFFALO · NIH-11053594
This study is looking at how psilocybin, a natural substance found in some mushrooms, might help reduce the urge to smoke by testing it on rats, which could lead to new ways to help people quit smoking.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STATE UNIVERSITY OF NEW YORK AT BUFFALO (nih funded) |
| Locations | 1 site (AMHERST, UNITED STATES) |
| Trial ID | NIH-11053594 on ClinicalTrials.gov |
What this research studies
This research explores the effects of psilocybin, a psychedelic compound, on nicotine self-administration in rats. The study aims to understand how psilocybin may influence the motivation to consume nicotine, which could have implications for treating smoking addiction. It also examines how the context in which psilocybin is administered, including the animal's internal state and environment, affects its impact. By using an animal model, the research seeks to provide insights into the potential therapeutic benefits of psilocybin for nicotine dependence.
Who could benefit from this research
Good fit: Ideal candidates for potential benefits from this research would be individuals with nicotine dependence or those seeking to quit smoking.
Not a fit: Patients who do not smoke or are not interested in quitting nicotine may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for individuals struggling with nicotine addiction.
How similar studies have performed: Other research has shown promising results with psychedelic compounds in treating substance use disorders, suggesting that this approach may also be effective.
Where this research is happening
AMHERST, UNITED STATES
- STATE UNIVERSITY OF NEW YORK AT BUFFALO — AMHERST, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MEYER, PAUL J — STATE UNIVERSITY OF NEW YORK AT BUFFALO
- Study coordinator: MEYER, PAUL J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.